The role of integrins in the pathogenesis of inflammatory bowel disease: Approved and investigational anti-integrin therapies

Med Res Rev. 2020 Jan;40(1):245-262. doi: 10.1002/med.21601. Epub 2019 Jun 19.

Abstract

Inflammatory bowel disease (IBD) is characterized by uncontrolled inflammation in the gastrointestinal tract. The underlying pathobiology of IBD includes an increase in infiltrating gut-homing lymphocytes. Although lymphocyte homing is typically a tightly regulated and stepwise process involving multiple integrins and adhesion molecules expressed on endothelial cells, the distinct roles of integrin-expressing immune cells is not fully understood in the pathology of IBD. In this review, we detail the involvement of integrins expressed on specific lymphocyte subsets in the pathogenesis of IBD and discuss the current status of approved and investigational integrin-targeted therapies.

Keywords: Crohn's disease, ulcerative colitis; anti-integrin therapy; inflammatory bowel disease; integrins.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Drugs, Investigational / pharmacology
  • Drugs, Investigational / therapeutic use*
  • Gastrointestinal Tract / pathology
  • Humans
  • Inflammatory Bowel Diseases / drug therapy*
  • Inflammatory Bowel Diseases / metabolism
  • Inflammatory Bowel Diseases / pathology*
  • Integrins / metabolism*
  • Molecular Targeted Therapy
  • T-Lymphocytes / drug effects
  • T-Lymphocytes / immunology

Substances

  • Drugs, Investigational
  • Integrins